"Intestinal Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the INTESTINES.
| Descriptor ID |
D007414
|
| MeSH Number(s) |
C04.588.274.476.411 C06.301.371.411 C06.405.249.411 C06.405.469.491
|
| Concept/Terms |
Intestinal Neoplasms- Intestinal Neoplasms
- Intestinal Neoplasm
- Neoplasm, Intestinal
- Neoplasms, Intestinal
- Intestines Neoplasms
- Intestines Neoplasm
- Neoplasm, Intestines
- Neoplasms, Intestines
Cancer of Intestines- Cancer of Intestines
- Intestines Cancers
- Cancer of the Intestines
- Intestines Cancer
- Cancer, Intestines
- Cancers, Intestines
- Intestinal Cancer
- Cancer, Intestinal
- Cancers, Intestinal
- Intestinal Cancers
|
Below are MeSH descriptors whose meaning is more general than "Intestinal Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Intestinal Neoplasms".
This graph shows the total number of publications written about "Intestinal Neoplasms" by people in this website by year, and whether "Intestinal Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1997 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 2 | 1 | 3 |
| 2002 | 4 | 0 | 4 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 3 | 0 | 3 |
| 2018 | 3 | 0 | 3 |
| 2019 | 2 | 1 | 3 |
| 2020 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intestinal Neoplasms" by people in Profiles.
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
-
Clinicopathologic and Molecular Characterization of Inflammatory Bowel Disease-Associated Neuroendocrine Carcinomas and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Mod Pathol. 2024 Oct; 37(10):100566.
-
Creation of a Quality Payment Program Measure for Mismatch Repair or Microsatellite Instability Biomarker Testing Status in Colorectal, Endometrial, Gastroesophageal, or Small Bowel Carcinoma. Arch Pathol Lab Med. 2024 Jun 01; 148(6):728-734.
-
Primary Tumor Resection and Its Implications in the Modern Treatment Era of Metastatic Small Bowel Neuroendocrine Tumors : Editorial on: "Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors". Ann Surg Oncol. 2024 Apr; 31(4):2187-2189.
-
Association between Body Mass Index and Risk of Gastric Cancer by Anatomic and Histologic Subtypes in Over 500,000 East and Southeast Asian Cohort Participants. Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1727-1734.
-
Intestinal Cancer and Dysplasia in Crohn's Disease. Gastroenterol Clin North Am. 2022 06; 51(2):369-379.
-
Risk of Small Bowel Adenocarcinoma, Adenomas, and Carcinoids in a Nationwide Cohort of Individuals With Celiac Disease. Gastroenterology. 2020 11; 159(5):1686-1694.e2.
-
Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.
-
Baicalein, an enteric microbial metabolite, suppresses gut inflammation and cancer progression in ApcMin/+ mice. Clin Transl Oncol. 2020 Jul; 22(7):1013-1022.
-
Getting to the Root of the Problem. Gastroenterology. 2020 04; 158(5):1229-1231.